Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

1,440

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

January 5, 2022

Study Completion Date

January 5, 2022

Conditions
COVID-19 Pneumonia
Interventions
BIOLOGICAL

COVAX

2 doses of Covid-19 vaccine

Trial Locations (5)

Unknown

Nan'an Center for Disease Control and Prevention, Quanzhou

Yong'an Center for Disease Control and Prevention, Sanming

Youxi Center for Disease Control and Prevention, Sanming

Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren

Linli County Center for Disease Control and Prevention, Changde

All Listed Sponsors
collaborator

Hunan Provincial Center for Disease Control and Prevention

OTHER

collaborator

Guizhou Center for Disease Control and Prevention

OTHER

collaborator

Center for Disease Control and Prevention, Fujian

OTHER

collaborator

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

lead

China National Biotec Group Company Limited

INDUSTRY

NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes | Biotech Hunter | Biotech Hunter